The NV1050™ device performed to manufacturer specifications and demonstrated a dramatic reduction of active virus after 30 minutes of exposure in aerosol form. The live SARS-CoV-2 virus was not detectable after 30 minutes, (levels were below the 120 TCID50 / ml limit of quantification).
Every effort was made to simulate a real-life environment in the chamber while taking into consideration the special precautions needed when working with a Biosafety Level 3 Pathogen. Taking into consideration the starting concentration of active SARS-CoV-2 virus, the volume aerosolized, and the volume inoculated, one could assume that the likelihood of entering an environment with this quantity of pathogen in a real-life circumstance to be unlikely.
When aerosolizing pathogens and collecting said pathogens, there are variables that cannot be fully accounted for, namely, placement of pathogen, collection volume, collection points, drop rate, surface saturation, viral destruction on collection, viral destruction on nebulization, and possibly others. Every effort was made to address these constraints with the design and execution of the trials and these efforts are reflected in the meaningful recovery of virus in the control test.
Taking these variables into account, there was a large amount of removal achieved by the NV1050™ device in the first 30 minutes. The reduction in air was significant and consistent with the manufacturer’s claims. Overall, the NV1050™ device showed substantial efficacy in the removal of SARS-CoV-2 USA-CA1/2020 out of the breathable air.